This document provides information on paediatric asthma, including:
1) It defines asthma as a chronic inflammatory airway disorder with reversible obstruction. There are different types and severities of asthma.
2) Status asthmaticus is a severe exacerbation that does not improve with standard therapy and can lead to life-threatening respiratory insufficiency.
3) Management of an asthma exacerbation involves risk assessment, clinical assessment, workup, medical management including bronchodilators and steroids, and criteria for ICU admission if the patient is not improving. Intubation may be needed for refractory cases.
Differences between Paediatric and Adult airway gourav_singh
These slides contain a brief discussion about what all common differences between pediatric and adult airway can be found if you are in an ENT OPD or during Anesthesia.
Just a brief discussion.
Differences between Paediatric and Adult airway gourav_singh
These slides contain a brief discussion about what all common differences between pediatric and adult airway can be found if you are in an ENT OPD or during Anesthesia.
Just a brief discussion.
SEMS 2014: Ang Shiang Hu - Life threatening asthma Rahul Goswami
The Critical Care track of the Society for Emergency Medicine in Singapore Annual Scientific Meeting 2014.
For more information and conference videos, go to singem.blogspot.sg
Asthma Signs and Symptoms, Severity Classification, GINA and ATS Classification, Step-up Management of Chronic Asthma and Management of Acute Exacerbation of Asthma
SEMS 2014: Ang Shiang Hu - Life threatening asthma Rahul Goswami
The Critical Care track of the Society for Emergency Medicine in Singapore Annual Scientific Meeting 2014.
For more information and conference videos, go to singem.blogspot.sg
Asthma Signs and Symptoms, Severity Classification, GINA and ATS Classification, Step-up Management of Chronic Asthma and Management of Acute Exacerbation of Asthma
Neonatal sepsis
Made Easy to understand all the students
DR ATIQUR RAHMAN KHAN
MBBS,MD,DCH,MRCPS(GLASCOW),FRCP(UK)
Msc Counselling and Psychotherapy
Member American Academy of Paediatrics(AAP)
Member British Association of Perinatal Medicine(BAPM)
Member British Association for Parenteral and Enteral Nutrition(BAPEN)
Associate Member Royal College of Paediatrics and Child Health(RCPCH)
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
India Diagnostic Labs Market: Dynamics, Key Players, and Industry Projections...Kumar Satyam
According to the TechSci Research report titled “India Diagnostic Labs Market Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2019-2029,” the India Diagnostic Labs Market was valued at USD 16,471.21 million in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 11.55% through 2029. This significant growth can be attributed to various factors, including collaborations and partnerships among leading companies, the expansion of diagnostic chains, and increasing accessibility to diagnostic services across the country. This comprehensive report delves into the market dynamics, recent trends, drivers, competitive landscape, and benefits of the research report, providing a detailed analysis of the India Diagnostic Labs Market.
Collaborations and Partnerships
Collaborations and partnerships among leading companies play a pivotal role in driving the growth of the India Diagnostic Labs Market. These strategic alliances allow companies to merge their expertise, strengthen their market positions, and offer innovative solutions. By combining resources, companies can enhance their research and development capabilities, expand their product portfolios, and improve their distribution networks. These collaborations also facilitate the sharing of technological advancements and best practices, contributing to the overall growth of the market.
Expansion of Diagnostic Chains
The expansion of diagnostic chains is a driving force behind the growing demand for diagnostic lab services. Diagnostic chains often establish multiple laboratories and diagnostic centers in various cities and regions, including urban and rural areas. This expanded network makes diagnostic services more accessible to a larger portion of the population, addressing healthcare disparities and reaching underserved populations. The presence of diagnostic chain facilities in multiple locations within a city or region provides convenience for patients, reducing travel time and effort. A broader network of labs often leads to reduced waiting times for appointments and sample collection, ensuring that patients receive timely and efficient diagnostic services.
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a significant driver for the demand for diagnostic lab services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require regular monitoring and diagnostic testing for effective management. The rise in chronic diseases necessitates the use of advanced diagnostic tools and technologies, driving the growth of the diagnostic labs market. Additionally, early diagnosis and timely intervention are crucial for managing chronic diseases, further boosting the demand for diagnostic lab services.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
2. Definition Of Bronchial Asthma
Asthma is chronic
inflammatory disorder of the
airways with reversible
obstruction
3. TYPES OF ASTHMA
NATURAL COURSE OF DISEASE:;
1)Recurrent wheezing in early childhood,usually
triggered by common respiratory viral infection and
resolves during the preschool years and there is less
asthma risk is later life
2)Chronic asthma ,Associated with allergy that
persist into later childhood and offen adulthood
4. According to disease severity.
Intermittent or Persistent(mild ,moderate and severe)
According to the control
Well ,not well, or very poorly control
According to treatment response
Easy to treat, well controlled with low levels of
controller therapy
Difficult to treat, well controlled with high levels of
controller therapy.
5. Exacerbators, despite being well controlled continue
to have severe exacerbations.
Refractory Asthma,continue to have poorly controlled
asthma despite multiple and high levels of controller
therapies
6. Lung Function Test
PEF :-used to monitoring airflow obstruction
Normal more than 80%, Mild less than 70% Moderate
40-69% and Severe less the 40%,
FEV1 : FVC :-less than 0.8 indicate significant airflow
obstruction
Spirometry:- used to access the airflow limitation in
patient who are at risk of severe asthma exacerbation
7. Factors contributing to asthma severity
Tobacco smoke
Animal danders,pets
Pests(mice rats)
Dust mites
Cockroaches
Wood or coal burning smoke
Strong chemical odours and perfumes
Dust
8. DEFINITION OF STATUS ASTHMATICUS
Severe exacerbation of asthma that does not
improve with standard therapy is termed
status asthmaticus.
Airflow obstruction during exacerbation can
become extensive resulting in life
threatening respiratory insufficiency.
9. Management
Risk assessment at the time of presentation
● Onset of current exacerbation
● Frequency and severity of night and day time
● symptoms and activity limitation
● Frequency of rescue bronchodilators used
● Potential triggers
● History of systemic steroids courses,
● Emergency department visits,hospitalization,
● Intubation or life threatening episode.
10. Clinical Assessment
● Physical examination finding:- vitals sign,
breathlessness, tachypnea retraction,use of
accessory muscles of respiration,anxiety level,
altered level of consciousness,unable to talk in
sentences,Irritable ,exhausted,
● Pulse oximetry
● Lung function should be deferred in patient of
moderate to severe asthma
12. Medical Management
O2 with mask/nasal prongs to keep saturation more than 92 %
Use of short acting B agonist
Salbutamol Nebulization (0.15-0.3 mg /kg) every 20 min for 1 Hr Or
0.5 mg/Hr continuous nebulization
Steroids (Oral /IV)
1)Methylprednisolone 1-2 mg/kg/day BD (Max 60mg)
2)Inj Dexamethasone single(oral/IV/IM) 0.6mg/kg,Max 16 mg,
has been found to be an effective alternative to prednisone and
with low incidence of emesis
14. Anticholinergic drugs
Ipratropium Bromide/ Atrovent Nebulization
0.25mg If age less then 12 yrs
0.5 mg if more then 12 yrs Q6-8H
When use in combination with salbutamol,
Ipratropium can improve lung function and reduce
rate of hospitation due synergistic effect.
16. Indication for ICU admission
1)Altered sensorium
2)Use of continuous B2 agonist
3)Marked decreased air entry
4)Rising PC02
5)Exhaustion
6)Severe respiratory distress with possibility of
respiratory failure
17. According to latest concept every effort
should be made to relieve bronchospasm and
prevent respiratory failure in order to avoid
mechanical ventilation.
If at all necessary, elective intubation with
sedation (paralytic agent -Ketamine) is safer
than emergency intubation.
18. If patient is shifted to ICU/Ward and still not
improved
Magnesium Sulphate 25 -75 mg/kg over 20 min
Max 2.5 Gm.
Administration of Magnesium Sulphate needs
monitoring of Serum levels and cardiovascular status
19. Inj Terbutaline:-Continuous IV infusion 2-10 microgram/kg
loading dose,followed by 0.1-0.4 microgram/min
We can increase the dose 0.1-0.2 microgram/kg/min depending on
the clinical response
Terbutaline Infusion also needs cardiorespiratory monitoring,Pulse
Oximetry ,Blood pressure.
Adverse Effects:-
Tremors,Tachycardia,Palpitation,Arrhythmia,Hypertension,
Headache,Nausea,Vomiting.
20. If after all this medical
management patient is still in
respiratory distress and clinically
deteriorating then elective
intubation is preferred
21. Criteria for Intubation
Apnea / Respiratory Arrest
Decrease level of Consciousness
Impending respiratory failure
Significant rising Pco2 and fatigue
22. Mechanical Ventilator Parameter
In Asthmatic patients, mechanical Ventilation aims to
achieve adequate oxygenation while tolerating mild to
moderate hypercapnia (50-70 mmHg) to minimize
barotrauma
Volume cycled ventilators, using short inspiratory and
long expiratory time(I:E 1:3) ,with low PEEP
Tidal Volume 6-10 ml/kg
Ventilator Rate according to age.